Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant
The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant of the present invention is used, the level of antigen specific antibody induction is synergistically increased and Th1 type immune response is also induced. Therefore, the adjuvant of the present invention can be very effectively used as an adjuvant in the formulation of preventive and therapeutic vaccines for viral or parasitic infection and cancer.
1. An adjuvant comprising one or more lipopeptide(s) selected from the group consisting of Pam3Cys-SKKKK and Pam3Cys-SR8, and poly I:C(polyinosinic:polycytidylic acid), wherein the lipopeptide and poly I:C synergistically stimulate induction of adaptive immune responses.
2. The adjuvant according to claim 1 , wherein the poly I:C is about 50-2,000 bp in length.
3. A vaccine composition comprising the adjuvant of claim 1 and at least one antigen.
4. The vaccine composition according to claim 3 , wherein the antigen is selected as a single or multiple component(s) from the group consisting of a protein of a pathogen, a recombinant protein, a peptide, a hapten, a polysaccharide, a glycoprotein, a lipopolysaccharide, a DNA molecule (polynucleotide), a cancer cell, a micro-organism, and mixtures thereof.
5. The vaccine composition according to claim 3 , wherein the antigen is selected from the group consisting of L-HBsAg, influenza HA, S-protein, and preS.
6. The vaccine composition according to claim 3 , wherein the vaccine is capable of efficiently inducing cell mediated immune response and producing antigen-specific antibodies.
7. The vaccine composition according to claim 6 , wherein the antibodies comprise IgG1, IgG2a and IgG2b type antibodies.
8. A pharmaceutical composition comprising the adjuvant of claim 1 and at least one active ingredient.
9. The pharmaceutical composition according to claim 8 , further comprising at least one ingredient selected from the group consisting of pharmaceutically acceptable carriers, pharmaceutically acceptable additives and adjuvants.
10. A method for generating an antibody comprising administrating the vaccine composition of claim 3 to a subject in need thereof.
11. The method according to claim 10 , wherein the method facilitates mass-production of an antibody.
12. A method for enhancing Th1 immune response comprising administrating the vaccine composition of claim 3 to a subject in need thereof.
13. A method for inducing an immune response against a viral or parasitic infection comprising administrating the adjuvant of claim 1 and at least one viral antigen or parasite antigen to a subject in need thereof.
14. The method according to claim 13 , wherein the viral antigen is selected from the group consisting of influenza virus antigen (HA: haemagglutinin or neuraminidase antigen), human papilloma virus (HPV) antigen, human immunodeficiency virus (HIV) antigen (GP-120, GP-160), vesicular stomatitis virus antigen (vesicular stomatitis virus glycoprotein), cytomegalovirus (CMV) antigen, hepatitis antigen [hepatitis A(HAV), B(HBV), C(HCV), D(HDV) and G(HGV): L-HBsAg, S-HBsAg, M-HBsAg, pre S], respiratory syncytial virus (RSV) antigen and herpes simplex virus antigen.
15. The method according to claim 13 , wherein the parasite is selected from the group consisting of protozoa, nematoda, trematoda and cestoda.
16. A method for inducing an immune response against cancer comprising administrating the adjuvant of claim 1 and at least one cancer-specific antigen to a subject in need thereof.
17. The method according to claim 16 , wherein the cancer is selected from the group consisting of renal cell carcinoma, a melanoma, a chronic lymphocytic leukemia, a lung cancer, a cervical cancer, a stomach cancer, a thyroid cancer, a pancreatic cancer, a breast cancer, a prostate cancer, an ovarian cancer, a cholangioma, a liver cancer, a colon cancer, and a rectal cancer.
18. The method according to claim 16 , wherein the cancer-specific antigen is selected from the group consisting of gp100, MART-1 and MAGE-1, tyrosinase, CEA (cancer embryonic antigen), PSA (prostate specific antigen), HER2/neu, MAGE-1, MAGE-2, MAGE-3, NY-ESO-1, MUC-1, SART-1 or SART-3, TERT (telomerase reverse transcriptase) or a partial peptide derived from TERT, WT1 or a partial peptide derived from WT1, Survivin-2B or a partial peptide derived from Survivin-2B, gp75, MDM2, telomerase, alpha-1 fetoprotein, CA125, CA15-3, CA19-9, G250 and NY-ESO-1.
19. A vaccine kit comprising the adjuvant of claim 1 and technical instructions with information on the administration and dosage of the adjuvant.